Den Europæiske Union - dansk - EMA (European Medicines Agency)

life molecular imaging gmbh - florbetaben (18f) - radionuclide imaging; alzheimer disease - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. neuraceq er et radioaktivt lægemiddel, der er angivet for positron-emissions-tomografi (pet) - scanning af β-amyloid neuritic plak tæthed i hjernen hos voksne patienter med kognitiv svækkelse, der er ved at blive evalueret for alzheimers sygdom (ad) og andre årsager til kognitiv svækkelse. neuraceq bør anvendes i forbindelse med en klinisk evaluering. en negativ scanning viser, sparsomme eller ingen plaques, der ikke er i overensstemmelse med en diagnose af ad.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaxim sweden ab - bacitracin, benzylpenicillinkalium, neomycin - intramammær salve - kvæg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cis bio international oris ind. - natriummolybdat (99m-mo) - radionuklidgenerator

Danmark - dansk - SEGES Landbrug & Fødevarer

syngenta nordics a/s - pinoxaden, cloquintocet-mexyl, cloquintocet - emulsionskoncentrat - 100 g/l pinoxaden; 25 g/l cloquintocet-mexyl; (~ 17,7 g/l cloquintocet

Danmark - dansk - SEGES Landbrug & Fødevarer

syngenta nordics a/s - pinoxaden, cloquintocet-mexyl, cloquintocet - emulsionskoncentrat - 50 g/l pinoxaden; 12,5 g/l cloquintocet-mexyl; (~ 8,85 g/l cloquintocet

Danmark - dansk - SEGES Landbrug & Fødevarer

fmc europe nv, agrochemical products group - linuron, clomazon - flydende middel - 250 g/l linuron; 45 g/l clomazon

Danmark - dansk - SEGES Landbrug & Fødevarer

syngenta nordics a/s - prothioconazol, benzovindiflupyr - emulsionskoncentrat - 150 g/l prothioconazol; 75 g/l benzovindiflupyr

Danmark - dansk - SEGES Landbrug & Fødevarer

vivagro - additiv - vandopløseligt granulat - 1000 g/l additiv

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).